Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1991005805) MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/005805 International Application No.: PCT/US1990/006030
Publication Date: 02.05.1991 International Filing Date: 19.10.1990
Chapter 2 Demand Filed: 13.05.1991
IPC:
C07K 16/28 (2006.01) ,C07K 16/30 (2006.01) ,C07K 16/46 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
Applicants:
TRUSTEES OF DARTMOUTH COLLEGE [US/US]; 311 McNutt Hall P.O. Box 7 Hanover, NH 03755, US
Inventors:
SHEN, Li; US
FANGER, Michael, W.; US
Agent:
DeCONTI, Giulio, A., Jr. ; Lahive & Cockfield 60 State Street Boston, MA 02109, US
Priority Data:
424,88320.10.1989US
Title (EN) MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR
(FR) ANTICORPS MONOCLONAL SPECIFIQUE POUR LEUR RECEPTEUR IgA
Abstract:
(EN) Monoclonal antibodies which react specifically to Fc receptor for IgA of human effector cells are disclosed. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.). For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc-alpha receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can specifically lyse target cells.
(FR) L'invention concerne des anticorps monoclonaux qui réagissent de manière spécifique au récepteur Fc pour IgA de cellules effectrices humaines. Les anticorps sont utiles pour cibler des cellules effectrices humaines (p. ex. des macrophages) contre une cellule cible (p. ex. une cellule cancéreuse, un agent infectieux, etc). A cet effet des anticorps bifonctionnels ou des hétéroanticorps peuvent être construits, lesquels contiennent la région de liaison dérivée d'un anticorps récepteur anti-Fc-alpha et la région de liaison d'un anticorps spécifique à la cible. Les cellules effectrices ciblées peuvent effectuer la lyse spécifique des cellules cibles.
Designated States: CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0496818ES2132072JPH05504677CA2067244DE000069033181DK0496818